Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Chugai Offloading Xeloda to Cheplapharm after German Firm Plants Flag in Japan
Chugai Pharmaceutical said on November 6 that it will transfer the business of cancer drug Xeloda (capecitabine) to German-based Cheplapharm in Japan next year. Chugai in-licensed Xeloda from Roche and is the marketing authorization (MA) holder in the country. The…
To read the full story
Related Article
- Chugai to Transfer Tarceva to Cheplapharm in April
January 15, 2025
- Cheplapharm Takes Over Xeloda from Chugai in Japan
February 2, 2024
- Cheplapharm Initiates LLP Acquisitions in Japan, Eyes 10 Asset Takeovers in 2024: Local Head
December 15, 2023
BUSINESS
- Japan IP High Court Upholds Invalidation of Key Trazenta Dosage Patent
February 19, 2026
- ONODERA GT Pharma Targets 2026 Filings for Two Gene Therapies
February 19, 2026
- Sumitomo Pharma Sees iPSC Therapy as Potential US$1 Billion Global Product
February 18, 2026
- AstraZeneca Launches Japan Registry Study of Imfinzi in Limited-Stage SCLC
February 18, 2026
- Asahi Kasei Gets Global Rights to Alchemedicine’s Lead Compounds
February 18, 2026
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…